Beneficial Ownership Report · SCHEDULE 13G
Vicore Pharma Holding AB
Beneficial Ownership Report
Structured filing — SCHEDULE 13G
primary_doc.xml
Subject company
- Company
- Vicore Pharma Holding AB
- Company CIK
- 0002124403
- Street
- Kornhamnstorg 53
- City
- Stockholm
- State / country code
- V7
- Postal code
- SE-111 27
Statement details
- Security class
- Common Shares, no par value
- Event date
- 06/30/2026
- Rule designation
- Rule 13d-1(d)
Reporting person 1
- Name
- HBM Healthcare Investments (Cayman) Ltd.
- Citizenship / organization
- E9
- Reporting person type
- CO
- Aggregate amount owned
- 22,505,819.00
- Percent of class
- 8
- Sole voting power
- 22,505,819.00
- Shared voting power
- 0.00
- Sole dispositive power
- 22,505,819.00
- Shared dispositive power
- 0.00
- Aggregate excludes certain shares
- N
- Comments
- Voting and investment power over the shares held by HBM Healthcare Investments (Cayman) Ltd. is exercised by the board of directors of HBM Healthcare Investments (Cayman) Ltd. (the "Board"). The Board consists of Jean-Marc LeSieur, Richard H. Coles, Sophia Harris, Dr. Andreas Wicki, Mark Kronenfeld, M.D., and Richard Paul Woodhouse, none of whom has individual voting or investment power with respect to the shares.
Item 1
Issuer
Vicore Pharma Holding AB
Principal executive office address
Kornhamnstorg 53, SE-111 27, Stockholm, Sweden
Item 2
Citizenship
Cayman Islands, British West Indies
Filing person
HBM Healthcare Investments (Cayman) Ltd. (the "Reporting Person")
Principal business or residence address
Governors Square, 23 Lime Tree Bay Avenue, PO Box 30852, Grand Cayman, KY1-1204, Cayman Islands
Item 3
Not applicable indication
Y
Item 4
Percent of class
As of June 30, 2026, the Reporting Person may have been deemed the beneficial owner of approximately 8.1% of the Common Shares outstanding, based on 281,525,593 Common Shares outstanding as of June 30, 2026, as reported in Exhibit 99.1 to the Issuer's current report on Form 6-K filed with the Securities and Exchange Commission on August 21, 2026. As of the date hereof, the Reporting Person may be deemed the beneficial owner of approximately 8% of the Common Shares outstanding. The percentage set forth herein is calculated based on 281,644,509 Common Shares outstanding as of September 30, 2026, as reported in Exhibit 99.1 to the Issuer's current report on Form 6-K filed with the Securities and Exchange Commission on September 30, 2026.
Amount beneficially owned
The CUSIP provided in this statement is the CUSIP for the Issuer's American Depositary Shares ("ADSs"). Each one ADS represents ten (10) Common shares, no par value, of the Issuer ("Common Shares"). The ADSs are not deemed a separate class of securities for purposes of calculating beneficial ownership under Section 13(d) of the Securities Exchange Act of 1934, as amended. Accordingly, the Reporting Person's beneficial ownership is reported in this Schedule 13G in terms of Common Shares, not ADSs. However, the CUSIP provided in this statement is the CUSIP for the Issuer's ADSs because there is no CUSIP number assigned to the Common Shares. As of June 30, 2026, the Reporting Person may have been deemed the beneficial owner of 22,687,752 Common Shares. As of the date hereof, the Reporting Person may be deemed the beneficial owner of 22,505,819 Common Shares.
Sole voting power
22,505,819
Shared voting power
0
Sole dispositive power
22,505,819
Shared dispositive power
0
Item 5
Not applicable indication
Y
Item 6
Not applicable indication
Y
Item 7
Not applicable indication
Y
Item 8
Not applicable indication
Y
Item 9
Not applicable indication
Y
Item 10
Not applicable indication
Y
Signature 1
- Reporting person
- HBM Healthcare Investments (Cayman) Ltd.
- Signed
- /s/ Jean-Marc LeSieur
- Title
- Jean-Marc LeSieur, Managing Director
- Date
- 10/13/2026
Company context
Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company’s lead program, buloxibutid, is an oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF.